{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":21,"n_cols":5,"rows_kept":21,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[9,2,9,3],[10,2,10,3],[11,2,11,3],[12,2,12,3],[14,2,14,3],[15,2,15,3],[19,2,19,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910791912903321"]
[null,null,"Autore",null,"Jackson Emily <1966->"]
[null,null,"Titolo",null,"Law and the regulation of medicines / / Emily Jackson"]
[null,null,"Pubbl/distr/stampa",null,"Oxford ; ; Portland, Ore. : , : Hart Publishing, , 2012"]
[null,null,"ISBN",null,"1-84731-909-2"]
[{"$nulls":4},"1-4742-0077-X"]
[{"$nulls":4},"1-283-53952-7"]
[{"$nulls":4},"9786613851970"]
[{"$nulls":4},"1-84731-908-4"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (308 p.)"]
[null,null,"Disciplina",null,"344.410416"]
[null,null,"Soggetti",null,"Drugs - Law and legislation - Great Britain"]
[{"$nulls":4},"Pharmacy - Law and legislation - Great Britain"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references (pages 267-292)."]
[null,null,"Nota di contenuto",null,"What are medicines and why are they special? -- Clinical trials -- Licensing -- Pharmacovigilance and liability for dangerous drugs -- Marketing -- Funding and access to medicines in the UK -- Funding and access to medicines : a global problem -- The future of medicines I : pharmacogenetics -- The future of medicines II : enhancement."]
[null,null,null,"Sommario/riassunto","\"The principal purpose of this book is to tell the story of a medicine's journey through the regulatory system in the UK, from defining what counts as a medicine, through clinical trials, licensing, pharmacovigilance, marketing and funding. The question of global access to medicines is addressed because of its political importance, and because it offers a particularly stark illustration of the consequences of classifying medicines as a private rather than a public good. Two further specific challenges to the future of medicine's regulation are examined separately: first, pharmacogenetics, or the genetic targeting of medicines to subgroups of patients, and second, the possibility of using medicines to enhance well-being or performance, rather than treat disease. Throughout, the emphasis is on the role of regulation in shaping and influencing the operation of the medicines industry, an issue that is of central importance to the promotion of public health and the fair and equitable distribution of healthcare resources.\"--Bloomsbury Publishing."]